🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million infections per year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This milestone represents a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to results released by a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which combines a dual-drug approach. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Clinicians directly involved have voiced hope. Access to a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as essential to alleviate the strain of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.